1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Triptans: Products, Pipelines, Players, Patents and Prospects

Triptans: Products, Pipelines, Players, Patents and Prospects

  • June 2013
  • -
  • Greystone Research Associates

Triptans consist of a class of drugs called selective 5-hydroxytryptamine subtype 1 (5-HT1) receptor agonists. Migraine headaches are an established and growing market for patient-friendly drug delivery. Triptans constrict blood vessels in the brain and relieve swelling, a mechanism that is thought to provide palliative relief to migraine patients, but also have other properties that may help treat migraine symptoms. Worldwide, the highest prevalence of migraine occurs in North America. It is approximately 25 percent less frequent in Europe and Central and South America and approximately 67 percent less frequent in Asia and Africa. Most patients with migraine begin having the headaches in childhood, adolescence or early adulthood. The market and growth prospects for migraine therapeutics are substantial and have attracted an expanding list of players.

Highlights

• Analyzes and evaluates triptan drug classes and products and development-stage candidates and assesses risks and market potential
• Provides assessments of indications and markets for triptans and examines key market and commercialization factors
• Evaluates the impact of economic, technology, and regulatory factors on triptan drug commercialization
• Provides market data and forecasts to 2018
• Profiles market sector participants, their product development activities and business strategies

Table Of Contents

Triptans: Products, Pipelines, Players, Patents and Prospects
Summary of Contents

Executive Summary

The Market Opportunity

Market Dynamics
Indications and Prescribing
Demand Drivers
Competitive Landscape
Risks and Opportunities

Triptan Drug Classes

Almotriptans
Eletriptans
Frovatriptans
Naratriptans
Rizatriptans
Sumatriptans
Zolitriptans

Triptan Drug Products - Analysis, Market Data and Forecasts

Almotriptans
Branded Drugs
Patents and Exclusivity
Generics Outlook
Eletriptans
Branded Drugs
Patents and Exclusivity
Generics Outlook
Frovatriptans
Branded Drugs
Patents and Exclusivity
Generics Outlook
Naratriptans
Branded Drugs
Patents and Exclusivity
Generics Outlook
Rizatriptans
Branded Drugs
Patents and Exclusivity
Generics Outlook
Sumatriptans
Branded Drugs
Patents and Exclusivity
Generics Outlook
Zopitriptans
Branded Drugs
Patents and Exclusivity
Generics Outlook

Market Factors

Regulatory Issues
Patient Compliance and Ease of Use
Healthcare Economics

Company Profiles

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Dysmenorrhea  - Market Insights, Epidemiology and Market Forecast-2023

Dysmenorrhea  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Dysmenorrhea - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Migraine  - Market Insights, Epidemiology and Market Forecast-2023

Migraine  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Migraine - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

North America Pet Nutraceuticals Market

North America Pet Nutraceuticals Market

  • $ 3850
  • Industry report
  • December 2016
  • by Mordor Intelligence LLP

The total North American Pet Nutraceuticals market is valued at over $1528.4 million in 2015 and is projected to reach over $XX million by 2020 growing at a CAGR of XX% between the years 2015 and 2020. ...


Download Unlimited Documents from Trusted Public Sources

The future of the Pain Relief Industry in the UK

  • February 2017
    5 pages
  • Pain Relief  

  • United Kingdom  

View report >

Pain Relief Industry in the US

  • January 2017
    7 pages
  • Pain Relief  

  • United States  

View report >

Pain Relief Industry in the US

  • January 2017
    20 pages
  • Pain Relief  

    Therapy  

  • United States  

View report >

Otc Markets In China

3 months ago

Related Market Segments :

Pain Relief
Antimigraine

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.